

## CANCER VACCINES: TECHNOLOGIES AND GLOBAL MARKETS



PHM173B  
November 2016

Shalini Shahani Dewan  
*Project Analyst*

ISBN: 1-62296-383-0



**BCC Research**  
49 Walnut Park, Building 2  
Wellesley, MA 02481 USA  
866-285-7215 (toll-free within the USA),  
or (+1) 781-489-7301  
[www.bccresearch.com](http://www.bccresearch.com)  
[information@bccresearch.com](mailto:information@bccresearch.com)

**TABLE OF CONTENTS**

<b>TOPIC</b>	<b>PAGE NO.</b>
CHAPTER 1 INTRODUCTION	2
STUDY OBJECTIVES	2
REASONS FOR DOING THIS STUDY	2
CONTRIBUTIONS OF THE STUDY AND INTENDED AUDIENCE	2
SCOPE OF THE STUDY	3
METHODOLOGY	3
INFORMATION SOURCES	3
ANALYSTS' CREDENTIALS	4
RELATED BCC RESEARCH REPORTS	4
BCC RESEARCH WEBSITE	5
DISCLAIMER	5
CHAPTER 2 EXECUTIVE SUMMARY	7
<i>SUMMARY TABLE GLOBAL MARKET FOR CANCER VACCINES BY REGION, THROUGH 2021 (\$ MILLIONS)</i>	7
<i>SUMMARY FIGURE GLOBAL MARKET FOR CANCER VACCINES BY REGION, 2014-2021 (\$ MILLIONS)</i>	8
CHAPTER 3 OVERVIEW	10
DEFINITIONS	10
HISTORY OF CANCER AND ITS MANAGEMENT	12
<i>TABLE 1 HISTORY OF CANCER AND ITS MANAGEMENT</i>	12
CAUSES OF CANCER	14
GENETIC FACTORS	14
LIFESTYLE FACTORS	14
ENVIRONMENTAL FACTORS	14
TYPES OF CANCER-CAUSING GENES	15
IMMUNE SYSTEM AND CANCER	15
CLASSIFICATION OF CANCER	16
CANCER PREVENTION	17
TYPES OF CANCER TREATMENT	17
SURGERY	17
RADIATION THERAPY	18
CHEMOTHERAPY	18
IMMUNOTHERAPY	18
TARGETED THERAPY	18
CANCER VACCINES	19
LIVER CANCER	19
PROSTATE CANCER	21
Radical Retropubic Prostatectomy	21
Laparoscopic Prostatectomy	22
Radical Perineal Prostatectomy	22
Transurethral Resection of the Prostate	22
CERVICAL CANCER	23
CANCER VACCINES PLATFORM	24
Tumor Cell Vaccines	24

<b>TOPIC</b>	<b>PAGE NO.</b>
Cancer Stem Cell Vaccines	25
Peptide/Protein Vaccines	25
Antigen Vaccines	25
Anti-idiotypic Vaccines	25
Heat Shock Protein Vaccines	26
DNA and Vector-Based Vaccines	26
CHAPTER 4 REGULATORY ASPECTS	29
REGULATORY HISTORY OF APPROVED CANCER VACCINES	30
<i>TABLE 2 REGULATORY APPROVALS OF CANCER VACCINES, JUNE 2006 TO OCT. 2015</i>	31
RECALLS	31
<i>TABLE 3 PRODUCT RECALLS, DECEMBER 2013</i>	32
ORPHAN DRUG DESIGNATION	32
<i>TABLE 4 SIGNIFICANT ORPHAN DRUG DESIGNATIONS APPROVED, JAN. 2012 TO JUNE 2016</i>	32
FAST TRACK DESIGNATIONS	33
CHAPTER 5 NEW DEVELOPMENTS	35
PROSTATE CANCER	36
<i>TABLE 5 CLINICAL TRIALS ON PROSTATE CANCER VACCINES, AS OF JUNE 2016 (NO.)</i>	36
<i>TABLE 6 SIGNIFICANT PROSTATE CANCER VACCINES IN DEVELOPMENT, AS OF JUNE 2016</i>	37
BREAST CANCER	37
<i>TABLE 7 CLINICAL TRIALS ON BREAST CANCER VACCINES, AS OF JUNE 2016 (NO.)</i>	38
<i>TABLE 8 SIGNIFICANT BREAST CANCER VACCINES IN DEVELOPMENT, AS OF JUNE 2016</i>	38
CERVICAL CANCER	39
<i>TABLE 9 CLINICAL TRIALS ON CERVICAL CANCER VACCINES, AS OF JUNE 2016 (NO.)</i>	40
<i>TABLE 10 SIGNIFICANT CERVICAL CANCER VACCINES IN DEVELOPMENT, AS OF JUNE 2016</i>	40
LIVER CANCER	41
<i>TABLE 11 CLINICAL TRIALS ON LIVER CANCER VACCINES, AS OF JUNE 2016 (NO.)</i>	42
<i>TABLE 12 SIGNIFICANT LIVER CANCER VACCINES IN DEVELOPMENT, AS OF JUNE 2016</i>	42
LUNG CANCER	43
<i>TABLE 13 CLINICAL TRIALS ON LUNG CANCER VACCINES, AS OF JUNE 2016 (NO.)</i>	43
<i>TABLE 14 SIGNIFICANT VACCINES IN DEVELOPMENT FOR LUNG CANCER, AS OF JUNE 2016</i>	44
STOMACH CANCER	45
<i>TABLE 15 CLINICAL TRIALS ON STOMACH CANCER VACCINES, AS OF JUNE 2016 (NO.)</i>	45
<i>TABLE 16 SIGNIFICANT STOMACH CANCER VACCINES IN DEVELOPMENT, AS OF JUNE 2016</i>	45
COLORECTAL CANCER	46
<i>TABLE 17 CLINICAL TRIALS ON COLORECTAL CANCER VACCINES, AS OF JUNE 2016 (NO.)</i>	46

<b>TOPIC</b>	<b>PAGE NO.</b>
<i>TABLE 18 SIGNIFICANT COLORECTAL CANCER VACCINES IN DEVELOPMENT, AS OF JUNE 2016</i>	47
ESOPHAGEAL CANCER	47
<i>TABLE 19 CLINICAL TRIALS ON ESOPHAGEAL CANCER VACCINES, AS OF JUNE 2016 (NO.)</i>	48
<i>TABLE 20 SIGNIFICANT ESOPHAGEAL CANCER VACCINES IN DEVELOPMENT, AS OF JUNE 2016</i>	48
CHAPTER 6 MARKET ANALYSIS	50
MARKET BY TYPE	50
MARKET OVERVIEW	51
MARKET REVENUE	54
<i>TABLE 21 GLOBAL MARKET FOR CANCER VACCINES BY TYPE, THROUGH 2021 (\$ MILLIONS)</i>	55
<i>FIGURE 1 GLOBAL MARKET FOR CANCER VACCINES BY TYPE, 2014-2021 (\$ MILLIONS)</i>	55
MARKET SHARES	55
<i>TABLE 22 MARKET SHARE OF CANCER VACCINES BY TYPE, 2015 (%)</i>	56
<i>FIGURE 2 MARKET SHARE OF CANCER VACCINES BY TYPE, 2015 (%)</i>	56
MARKET BY REGION	56
MARKET OVERVIEW	57
MARKET REVENUE	58
<i>TABLE 23 GLOBAL MARKET FOR CANCER VACCINES BY REGION, THROUGH 2021 (\$ MILLIONS)</i>	59
<i>FIGURE 3 GLOBAL MARKET FOR CANCER VACCINES BY REGION, 2014-2021 (\$ MILLIONS)</i>	59
THERAPEUTIC VACCINES	60
Market Overview	62
Market Revenue	66
<i>TABLE 24 GLOBAL MARKET FOR THERAPEUTIC CANCER VACCINES BY REGION, THROUGH 2021 (\$ MILLIONS)</i>	67
<i>FIGURE 4 GLOBAL MARKET FOR THERAPEUTIC CANCER VACCINES BY REGION, 2014-2021 (\$ MILLIONS)</i>	67
Market Share	68
<i>TABLE 25 MARKET SHARES OF THERAPEUTIC VACCINES BY REGION, 2015 (%)</i>	68
<i>FIGURE 5 MARKET SHARES OF THERAPEUTIC VACCINES BY REGION, 2015 (%)</i>	68
PROPHYLACTIC VACCINES	69
Market Overview	70
Market Revenue	73
<i>TABLE 26 GLOBAL MARKET FOR PROPHYLACTIC CANCER VACCINES BY REGION, THROUGH 2021 (\$ MILLIONS)</i>	75
<i>FIGURE 6 GLOBAL MARKET FOR PROPHYLACTIC CANCER VACCINES BY REGION, 2014-2021 (\$ MILLIONS)</i>	75
Market Share	76
<i>TABLE 27 PROPHYLACTIC VACCINE MARKET SHARES BY REGION, 2015 (%)</i>	76
<i>FIGURE 7 PROPHYLACTIC VACCINE MARKET SHARES BY REGION, 2015 (%)</i>	76
CHAPTER 7 INDUSTRY STRUCTURE	79
PROPHYLACTIC CANCER VACCINES	79
MARKET LEADERS	79

<b>TOPIC</b>	<b>PAGE NO.</b>
<i>TABLE 28 LEADING MANUFACTURERS/SUPPLIERS OF PROPHYLACTIC CANCER VACCINES, 2015</i>	79
MARKET SHARE	79
<i>TABLE 29 MANUFACTURER/SUPPLIER MARKET SHARES OF PROPHYLACTIC CANCER VACCINES, 2015 (%)</i>	80
<i>FIGURE 8 MANUFACTURER/SUPPLIER MARKET SHARES OF PROPHYLACTIC CANCER VACCINES, 2015 (%)</i>	80
THERAPEUTIC CANCER VACCINES	80
MARKET LEADER	80
<i>TABLE 30 LEADING MANUFACTURERS/SUPPLIERS OF THERAPEUTIC CANCER VACCINES, 2015</i>	81
MARKET SHARE	81
<i>TABLE 31 MANUFACTURER/SUPPLIER MARKET SHARES OF THERAPEUTIC CANCER VACCINES, 2015 (%)</i>	81
<i>FIGURE 9 MANUFACTURER/SUPPLIER MARKET SHARES OF THERAPEUTIC CANCER VACCINES, 2015 (%)</i>	81
CHAPTER 8 MARKET BY APPLICATION	84
GLOBAL MARKET FOR CANCER VACCINES BY APPLICATION IN VARIOUS CANCERS	84
MARKET REVENUES	84
<i>TABLE 32 GLOBAL MARKET FOR CANCER VACCINES BY TYPE OF CANCER, THROUGH 2021 (\$ MILLIONS)</i>	85
<i>FIGURE 10 GLOBAL MARKET FOR CANCER VACCINES BY TYPE OF CANCER, 2014-2021 (\$ MILLIONS)</i>	85
MARKET SHARE	85
<i>TABLE 33 CANCER VACCINE MARKET SHARES BY TYPE OF CANCER, 2015 (%)</i>	86
<i>FIGURE 11 CANCER VACCINE MARKET SHARES BY TYPE OF CANCER, 2015 (%)</i>	86
PROSTATE CANCER	86
MARKET OVERVIEW	87
MARKET REVENUE	89
<i>TABLE 24 GLOBAL MARKET FOR THERAPEUTIC CANCER VACCINES BY REGION, THROUGH 2021 (\$ MILLIONS)</i>	89
<i>FIGURE 12 GLOBAL MARKET FOR PROSTATE CANCER VACCINES BY REGION, 2014-2021 (\$ MILLIONS)</i>	89
LIVER CANCER	90
MARKET OVERVIEW	90
MARKET REVENUES	92
<i>TABLE 35 GLOBAL MARKET FOR LIVER CANCER VACCINES BY REGION, THROUGH 2021 (\$ MILLIONS)</i>	93
<i>FIGURE 13 GLOBAL MARKET FOR LIVER CANCER VACCINES BY REGION, 2014-2021 (\$ MILLIONS)</i>	93
CERVICAL CANCER VACCINES	94
MARKET OVERVIEW	95
MARKET REVENUES	96
<i>TABLE 36 GLOBAL MARKET FOR CERVICAL CANCER VACCINES BY REGION, THROUGH 2021 (\$ MILLIONS)</i>	97
<i>FIGURE 14 GLOBAL MARKET FOR CERVICAL CANCER VACCINES BY REGION, 2014-2021 (\$ MILLIONS)</i>	97
OTHER VACCINES FOR CANCER	98

<b>TOPIC</b>	<b>PAGE NO.</b>
MARKET OVERVIEW	98
MARKET REVENUE	99
<i>TABLE 37 GLOBAL MARKET FOR OTHER CANCER VACCINES BY REGION, THROUGH 2021 (\$ MILLIONS)</i>	99
<i>FIGURE 15 GLOBAL MARKET FOR OTHER CANCER VACCINES BY REGION, 2014-2021 (\$ MILLIONS)</i>	99
CHAPTER 9 PATENT ANALYSIS	102
PATENTS BY YEAR	102
<i>TABLE 38 U.S. PATENTS BY YEAR, 2012 TO JUNE 2016 (NO.)</i>	102
<i>FIGURE 16 U.S. PATENTS BY YEAR, 2012 TO JUNE 2016 (NO.)</i>	103
PATENTS BY TYPE/CATEGORY	103
<i>TABLE 39 U.S. PATENTS BY CATEGORY, 2012 TO JUNE 2016 (NO.)</i>	103
<i>FIGURE 17 U.S. PATENTS BY CATEGORY, 2012 TO JUNE 2016 (NO.)</i>	103
PATENTS BY COMPANY	104
<i>TABLE 40 U.S. PATENTS BY COMPANY, 2012 TO JUNE 2016 (NO.)</i>	104
PATENTS BY COUNTRY	105
<i>TABLE 41 U.S. PATENTS BY COUNTRY, 2012 TO JUNE 2016 (NO.)</i>	105
<i>TABLE 42 U.S. PATENT SHARES BY COUNTRY, 2012 TO JUNE 2016 (NO./%)</i>	106
<i>FIGURE 18 U.S. PATENT SHARES BY COUNTRY, 2012 TO JUNE 2016 (%)</i>	106
PATENTS BY ASSIGNEE TYPE	107
<i>TABLE 43 U.S. PATENTS BY ASSIGNEE TYPE, JAN. 2012 TO JUNE 2016 (NO.)</i>	107
<i>FIGURE 19 U.S. PATENTS BY ASSIGNEE TYPE, JAN. 2012 TO JUNE 2016 (NO.)</i>	107
CHAPTER 10 CURRENT SITUATION	110
FACTORS AFFECTING CANCER VACCINES	110
INCREASING PREVALENCE OF CANCER	110
AGING POPULATION	111
LIFESTYLE CHANGES	111
APPROVALS FOR ADDITIONAL INDICATIONS	111
COMPETITION	112
INCREASED FUNDING	112
MANUFACTURERS' STRATEGIES	112
CHALLENGES IN CANCER VACCINE MARKET	114
CHAPTER 11 COMPANY PROFILES	116
ADAMIS PHARMACEUTICALS CORP.	116
ADURO BIOTECH INC.	116
ADVANTAGENE INC.	117
ADVAXIS INC.	118
ALPHAVAX INC.	118
ALTOR BIOSCIENCE CORP.	119
ANTIGEN EXPRESS INC.	120
BAVARIAN NORDIC A/S	120
BELLICUM PHARMACEUTICALS	121
BIOVEST INTERNATIONAL INC.	121
CASCADIAN THERAPEUTICS INC.	122
CELLEX THERAPEUTICS	123

<b>TOPIC</b>	<b>PAGE NO.</b>
CUREVAC AG	123
DENDREON CORP.	124
EMD SERONO	124
GALENA BIOPHARMA INC.	125
GENEXINE INC.	125
GLAXOSMITHKLINE	126
GLOBEIMMUNE INC.	126
GRADALIS	127
HEAT BIOLOGICS INC.	127
IMMUNE CELL THERAPY INC. (ICT)	128
IMMUNICUM AB	128
IMMUNOVATIVE THERAPIES LTD.	129
INOVIO PHARMACEUTICALS	129
ISA PHARMACEUTICALS B.V.	130
GEMVAX & KAEL CO. LTD.	130
MERCK &CO.	131
NEWLINK GENETICS CORP.	131
NOVARX CORP.	132
ONCOVIR INC.	132
OXFORD BIOMEDICA PLC	133
SOTIO AS	133
UBIVAC LLC	134
VICAL INC.	134
VACCINOGEN INC.	135
VAXON BIOTECH	135
CHAPTER 12 ABBREVIATIONS	138

**LIST OF TABLES**

<b>TABLE HEADING</b>	<b>PAGE NO.</b>
SUMMARY TABLE GLOBAL MARKET FOR CANCER VACCINES BY REGION, THROUGH 2021 (\$ MILLIONS)	7
TABLE 1 HISTORY OF CANCER AND ITS MANAGEMENT	12
TABLE 2 REGULATORY APPROVALS OF CANCER VACCINES, JUNE 2006 TO OCT. 2015	31
TABLE 3 PRODUCT RECALLS, DECEMBER 2013	32
TABLE 4 SIGNIFICANT ORPHAN DRUG DESIGNATIONS APPROVED, JAN. 2012 TO JUNE 2016	32
TABLE 5 CLINICAL TRIALS ON PROSTATE CANCER VACCINES, AS OF JUNE 2016 (NO.)	36
TABLE 6 SIGNIFICANT PROSTATE CANCER VACCINES IN DEVELOPMENT, AS OF JUNE 2016	37
TABLE 7 CLINICAL TRIALS ON BREAST CANCER VACCINES, AS OF JUNE 2016 (NO.)	38
TABLE 8 SIGNIFICANT BREAST CANCER VACCINES IN DEVELOPMENT, AS OF JUNE 2016	38
TABLE 9 CLINICAL TRIALS ON CERVICAL CANCER VACCINES, AS OF JUNE 2016 (NO.)	40
TABLE 10 SIGNIFICANT CERVICAL CANCER VACCINES IN DEVELOPMENT, AS OF JUNE 2016	40
TABLE 11 CLINICAL TRIALS ON LIVER CANCER VACCINES, AS OF JUNE 2016 (NO.)	42
TABLE 12 SIGNIFICANT LIVER CANCER VACCINES IN DEVELOPMENT, AS OF JUNE 2016	42
TABLE 13 CLINICAL TRIALS ON LUNG CANCER VACCINES, AS OF JUNE 2016 (NO.)	43
TABLE 14 SIGNIFICANT VACCINES IN DEVELOPMENT FOR LUNG CANCER, AS OF JUNE 2016	44
TABLE 15 CLINICAL TRIALS ON STOMACH CANCER VACCINES, AS OF JUNE 2016 (NO.)	45
TABLE 16 SIGNIFICANT STOMACH CANCER VACCINES IN DEVELOPMENT, AS OF JUNE 2016	45
TABLE 17 CLINICAL TRIALS ON COLORECTAL CANCER VACCINES, AS OF JUNE 2016 (NO.)	46
TABLE 18 SIGNIFICANT COLORECTAL CANCER VACCINES IN DEVELOPMENT, AS OF JUNE 2016	47
TABLE 19 CLINICAL TRIALS ON ESOPHAGEAL CANCER VACCINES, AS OF JUNE 2016 (NO.)	48
TABLE 20 SIGNIFICANT ESOPHAGEAL CANCER VACCINES IN DEVELOPMENT, AS OF JUNE 2016	48
TABLE 21 GLOBAL MARKET FOR CANCER VACCINES BY TYPE, THROUGH 2021 (\$ MILLIONS)	55
TABLE 22 MARKET SHARE OF CANCER VACCINES BY TYPE, 2015 (%)	56
TABLE 23 GLOBAL MARKET FOR CANCER VACCINES BY REGION, THROUGH 2021 (\$ MILLIONS)	59
TABLE 24 GLOBAL MARKET FOR THERAPEUTIC CANCER VACCINES BY REGION, THROUGH 2021 (\$ MILLIONS)	67
TABLE 25 MARKET SHARES OF THERAPEUTIC VACCINES BY REGION, 2015 (%)	68
TABLE 26 GLOBAL MARKET FOR PROPHYLACTIC CANCER VACCINES BY REGION, THROUGH 2021 (\$ MILLIONS)	75
TABLE 27 PROPHYLACTIC VACCINE MARKET SHARES BY REGION, 2015 (%)	76
TABLE 28 LEADING MANUFACTURERS/SUPPLIERS OF PROPHYLACTIC CANCER VACCINES, 2015	79
TABLE 29 MANUFACTURER/SUPPLIER MARKET SHARES OF PROPHYLACTIC CANCER VACCINES, 2015 (%)	80



<b>TABLE HEADING</b>	<b>PAGE NO.</b>
TABLE 30 LEADING MANUFACTURERS/SUPPLIERS OF THERAPEUTIC CANCER VACCINES, 2015	81
TABLE 31 MANUFACTURER/SUPPLIER MARKET SHARES OF THERAPEUTIC CANCER VACCINES, 2015 (%)	81
TABLE 32 GLOBAL MARKET FOR CANCER VACCINES BY TYPE OF CANCER, THROUGH 2021 (\$ MILLIONS)	85
TABLE 33 CANCER VACCINE MARKET SHARES BY TYPE OF CANCER, 2015 (%)	86
TABLE 24 GLOBAL MARKET FOR THERAPEUTIC CANCER VACCINES BY REGION, THROUGH 2021 (\$ MILLIONS)	89
TABLE 35 GLOBAL MARKET FOR LIVER CANCER VACCINES BY REGION, THROUGH 2021 (\$ MILLIONS)	93
TABLE 36 GLOBAL MARKET FOR CERVICAL CANCER VACCINES BY REGION, THROUGH 2021 (\$ MILLIONS)	97
TABLE 37 GLOBAL MARKET FOR OTHER CANCER VACCINES BY REGION, THROUGH 2021 (\$ MILLIONS)	99
TABLE 38 U.S. PATENTS BY YEAR, 2012 TO JUNE 2016 (NO.)	102
TABLE 39 U.S. PATENTS BY CATEGORY, 2012 TO JUNE 2016 (NO.)	103
TABLE 40 U.S. PATENTS BY COMPANY, 2012 TO JUNE 2016 (NO.)	104
TABLE 41 U.S. PATENTS BY COUNTRY, 2012 TO JUNE 2016 (NO.)	105
TABLE 42 U.S. PATENT SHARES BY COUNTRY, 2012 TO JUNE 2016 (NO./%)	106
TABLE 43 U.S. PATENTS BY ASSIGNEE TYPE, JAN. 2012 TO JUNE 2016 (NO.)	107

**LIST OF FIGURES**

<b>FIGURE TITLE</b>	<b>PAGE NO.</b>
SUMMARY FIGURE GLOBAL MARKET FOR CANCER VACCINES BY REGION, 2014-2021 (\$ MILLIONS)	8
FIGURE 1 GLOBAL MARKET FOR CANCER VACCINES BY TYPE, 2014-2021 (\$ MILLIONS)	55
FIGURE 2 MARKET SHARE OF CANCER VACCINES BY TYPE, 2015 (%)	56
FIGURE 3 GLOBAL MARKET FOR CANCER VACCINES BY REGION, 2014-2021 (\$ MILLIONS)	59
FIGURE 4 GLOBAL MARKET FOR THERAPEUTIC CANCER VACCINES BY REGION, 2014-2021 (\$ MILLIONS)	67
FIGURE 5 MARKET SHARES OF THERAPEUTIC VACCINES BY REGION, 2015 (%)	68
FIGURE 6 GLOBAL MARKET FOR PROPHYLACTIC CANCER VACCINES BY REGION, 2014-2021 (\$ MILLIONS)	75
FIGURE 7 PROPHYLACTIC VACCINE MARKET SHARES BY REGION, 2015 (%)	76
FIGURE 8 MANUFACTURER/SUPPLIER MARKET SHARES OF PROPHYLACTIC CANCER VACCINES, 2015 (%)	80
FIGURE 9 MANUFACTURER/SUPPLIER MARKET SHARES OF THERAPEUTIC CANCER VACCINES, 2015 (%)	81
FIGURE 10 GLOBAL MARKET FOR CANCER VACCINES BY TYPE OF CANCER, 2014-2021 (\$ MILLIONS)	85
FIGURE 11 CANCER VACCINE MARKET SHARES BY TYPE OF CANCER, 2015 (%)	86
FIGURE 12 GLOBAL MARKET FOR PROSTATE CANCER VACCINES BY REGION, 2014-2021 (\$ MILLIONS)	89
FIGURE 13 GLOBAL MARKET FOR LIVER CANCER VACCINES BY REGION, 2014-2021 (\$ MILLIONS)	93
FIGURE 14 GLOBAL MARKET FOR CERVICAL CANCER VACCINES BY REGION, 2014-2021 (\$ MILLIONS)	97
FIGURE 15 GLOBAL MARKET FOR OTHER CANCER VACCINES BY REGION, 2014-2021 (\$ MILLIONS)	99
FIGURE 16 U.S. PATENTS BY YEAR, 2012 TO JUNE 2016 (NO.)	103
FIGURE 17 U.S. PATENTS BY CATEGORY, 2012 TO JUNE 2016 (NO.)	103
FIGURE 18 U.S. PATENT SHARES BY COUNTRY, 2012 TO JUNE 2016 (%)	106
FIGURE 19 U.S. PATENTS BY ASSIGNEE TYPE, JAN. 2012 TO JUNE 2016 (NO.)	107